JP2024507533A5 - - Google Patents

Info

Publication number
JP2024507533A5
JP2024507533A5 JP2023550277A JP2023550277A JP2024507533A5 JP 2024507533 A5 JP2024507533 A5 JP 2024507533A5 JP 2023550277 A JP2023550277 A JP 2023550277A JP 2023550277 A JP2023550277 A JP 2023550277A JP 2024507533 A5 JP2024507533 A5 JP 2024507533A5
Authority
JP
Japan
Prior art keywords
rabies virus
recombinant
approximately
functional variant
genome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023550277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/017075 external-priority patent/WO2022178307A1/en
Publication of JP2024507533A publication Critical patent/JP2024507533A/ja
Publication of JP2024507533A5 publication Critical patent/JP2024507533A5/ja
Pending legal-status Critical Current

Links

JP2023550277A 2021-02-19 2022-02-18 遺伝子治療のための組み換え狂犬病ウイルス Pending JP2024507533A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163151542P 2021-02-19 2021-02-19
US63/151,542 2021-02-19
US202163241989P 2021-09-08 2021-09-08
US63/241,989 2021-09-08
PCT/US2022/017075 WO2022178307A1 (en) 2021-02-19 2022-02-18 Recombinant rabies viruses for gene therapy

Publications (2)

Publication Number Publication Date
JP2024507533A JP2024507533A (ja) 2024-02-20
JP2024507533A5 true JP2024507533A5 (https=) 2025-02-26

Family

ID=80953580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550277A Pending JP2024507533A (ja) 2021-02-19 2022-02-18 遺伝子治療のための組み換え狂犬病ウイルス

Country Status (7)

Country Link
US (1) US20220290164A1 (https=)
EP (1) EP4263825A1 (https=)
JP (1) JP2024507533A (https=)
KR (1) KR20230158476A (https=)
AU (1) AU2022224054A1 (https=)
CA (1) CA3208612A1 (https=)
WO (1) WO2022178307A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020051562A2 (en) 2018-09-07 2020-03-12 Beam Therapeutics Inc. Compositions and methods for improving base editing
EP3847254A4 (en) 2018-09-07 2022-08-10 Beam Therapeutics Inc. COMPOSITIONS AND METHODS FOR DELIVERING A NUCLEOBASE EDITING SYSTEM
AU2020215730A1 (en) 2019-01-31 2021-07-29 Beam Therapeutics Inc. Nucleobase editors having reduced non-target deamination and assays for characterizing nucleobase editors
CN120174005A (zh) 2019-02-13 2025-06-20 比姆医疗股份有限公司 具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
EP4034138A4 (en) 2019-09-27 2024-07-31 Beam Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
CA3196831A1 (en) 2020-09-25 2022-03-31 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
CA3230629A1 (en) * 2021-09-08 2023-03-16 Beam Therapeutics Inc. Viral guide rna delivery
WO2024163603A1 (en) * 2023-02-01 2024-08-08 Beam Therapeutics Inc. Chimeric pseudotyped recombinant rabies virus
WO2025111384A1 (en) * 2023-11-20 2025-05-30 Beam Therapeutics Inc. Compositions and methods for altering complement activation
CN119033805B (zh) * 2024-08-12 2025-07-22 华南农业大学 靶向抑制狂犬病病毒G基因和/或L基因的siRNA在制备抑制狂犬病的药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US7013219B2 (en) 1999-01-12 2006-03-14 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
EP1235914A2 (en) 1999-11-24 2002-09-04 Joseph Rosenecker Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
AU776576B2 (en) 1999-12-06 2004-09-16 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US6689558B2 (en) 2000-02-08 2004-02-10 Sangamo Biosciences, Inc. Cells for drug discovery
HUP0500722A2 (hu) * 2001-07-20 2005-11-28 The University of Georgia Research Foundation, Inc@Á Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén
MX341084B (es) 2009-11-02 2016-08-05 Univ Washington Composiciones de nucleasas terapéuticas y métodos.
EP2585598B1 (en) * 2010-06-24 2015-12-30 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Pan-lyssavirus vaccines against rabies
US10849975B2 (en) * 2011-02-03 2020-12-01 Thomas Jefferson University Multivalent vaccines for rabies virus and filoviruses
AU2016321383B2 (en) 2015-09-11 2021-12-23 Wm. Wrigley Jr. Company Synergistic antibacterial effects of magnolia bark extract and L-arginine, N-alpha-lauroyl ethyl ester on salivary bacteria
CN105139759B (zh) 2015-09-18 2017-10-10 京东方科技集团股份有限公司 一种拼接屏
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11155885B2 (en) * 2016-05-20 2021-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Real-time reverse transcriptase-polymerase chain reaction assay with modified probe for the diagnosis of rabies viruses and other lyssaviruses
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
GB201706945D0 (en) * 2017-05-02 2017-06-14 Medical Res Council Self-inactivating viral vector
WO2019013258A1 (ja) * 2017-07-11 2019-01-17 国立大学法人 東京大学 光制御性のウイルスタンパク質、その遺伝子、及びその遺伝子を含むウイルスベクター
CN109929839B (zh) * 2017-12-18 2021-02-12 华东师范大学 拆分型单碱基基因编辑系统及其应用
US11453893B2 (en) * 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control

Similar Documents

Publication Publication Date Title
JP2024507533A5 (https=)
EP3684925B1 (en) Non-integrating dna vectors for the genetic modification of cells
AU760770B2 (en) Episomally relicating vector, its preparation and use
Liu et al. Cationic liposome-mediated intravenous gene delivery
DE69429260T2 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
Ohwada et al. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver
Zeng et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation
Mulia et al. Advances in the development and the applications of nonviral, episomal vectors for gene therapy
NZ315295A (en) Ovine adenovirus oav287 and its use in gene therapy
CA2284399C (en) Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
JP2024533396A5 (https=)
Acsadi et al. Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells
Kaneda Improvements in gene therapy technologies
JPH02502605A (ja) 遺伝子発現の刺激方法
US20020142393A1 (en) Episomally replicating vector, its preparation and use
DE69810925T2 (de) Verwendung eines kationischen Polymer zur Herstellung von Nukleinsäure-Komplexe und verwandte Zusammensetzungen
Narumi et al. Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo
US6723708B2 (en) Use of lithium (Li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy
Bogomolova et al. Genetic engineering approaches to the development of modern therapeutics
JP2026513742A (ja) 合成回路及びその使用
US20010000228A1 (en) Use of a modified baculovirus containing exogenous nucleic acid for the manufacture of a medicament for delivering said nucleic acid to the hepatocytes
HK40031637B (en) Non-integrating dna vectors for the genetic modification of cells
HK40031637A (en) Non-integrating dna vectors for the genetic modification of cells
Lund Journal of Experimental Biochemistry & Physiology
WO1997028269A1 (en) Transduced human hematopoietic stem cells